Announced
Completed
Synopsis
Novozymes, a global biotechnology company, completed the acquisition of PrecisionBiotics Group, a provider of probiotics for human gut health, for $90m. “By becoming a part of Novozymes, we will get a global presence across businesses and new capabilities within science and discovery of new strains. This will help us to grow by developing new products where we can combine enzymes and probiotics,” Barry Kiely, PrecisionBiotics CEO and Co-Founder.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.